.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The TRAILBLAZER-ALZ 2 phase 3 trial evaluated donanemab, an antibody designed to clear amyloid plaques, in people with early symptomatic Alzheimer disease and PET evidence of amyloid and tau pathology. Participants receiving donanemab showed significantly less clinical decline than placebo at 76 weeks, with the treatment effect seen in both the low/medium-tau population and the overall study population. The therapy also produced substantial amyloid reduction. However, amyloid-related imaging abnormalities were common, and symptomatic events as well as treatment-related deaths occurred. Donanemab therefore represents a genuine shift toward disease-modifying treatment while simultaneously creating new requirements for diagnostic precision and safety monitoring. For HCPs, the practical message is that anti-amyloid therapy is not simply another symptomatic drug. Patients need biomarker confirmation, assessment of treatment eligibility and vascular risk, serial MRI surveillance, and clear counselling about expected benefits and potential harms. The trial also supports a broader shift toward treating Alzheimer disease earlier, before substantial functional decline has occurred. The evidence is therefore relevant both to dementia diagnosis and to therapeutic decision-making.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The TRAILBLAZER-ALZ 2 phase 3 trial evaluated donanemab, an antibody designed to clear amyloid plaques, in people with early symptomatic Alzheimer disease and PET evidence of amyloid and tau pathology. Participants receiving donanemab showed significantly less clinical decline than placebo at 76 weeks, with the treatment effect seen in both the low/medium-tau population and the overall study population. The therapy also produced substantial amyloid reduction. However, amyloid-related imaging abnormalities were common, and symptomatic events as well as treatment-related deaths occurred. Donanemab therefore represents a genuine shift toward disease-modifying treatment while simultaneously creating new requirements for diagnostic precision and safety monitoring. For HCPs, the practical message is that anti-amyloid therapy is not simply another symptomatic drug. Patients need biomarker confirmation, assessment of treatment eligibility and vascular risk, serial MRI surveillance, and clear counselling about expected benefits and potential harms. The trial also supports a broader shift toward treating Alzheimer disease earlier, before substantial functional decline has occurred. The evidence is therefore relevant both to dementia diagnosis and to therapeutic decision-making.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
